« Back to Directory of Resources

Treatments Under Development

Here you will find a list of current treatments under development:

Limit to treatments in



Page 1 of 612345...Last »

Brand Name:
Generic Name: dacetuzumab
Code Name: SGN-40
Company: Seattle Genetics Inc.
FDA Clinical Phase: 1

Description

Dacetuzumab is a monoclonal antibody that specifically binds to and works against a molecule called a CD40 receptor, which appears in abnormally high amounts in …

Brand Name:
Generic Name: ridaforolimus (formerly deforolimus)
Code Name: AP23573
Company: Ariad Pharmaceuticals & Merck
FDA Clinical Phase: 1

Description:

Ridaforolimus, formerly known as deforolimus, is …

Brand Name:
Generic Name:
Code Name: CX-4945
Company: Cylene
FDA Clinical Phase: 1

Description:

CX-4945 is an oral anti-cancer agent.  It inhibits CK2, an enzyme …

Brand Name:
Generic Name: Marizomib, salinosporamide A
Code Name: NPI-0052
Company: Triphase Research and Development I Corp
FDA Clinical Phase: 1

Description:
Marizomib (NPI-0052, salinosporide A) (news articles) is a novel proteasome inhibitor that suppresses tumor growth by inhibiting the …

Brand Name:
Generic Name:
Code Name: BI-505
Company: BioInvent
FDA Clinical Phase: 1

Description:

BI-505 is a fully human antibody that causes cell death. It …

Brand Name:  
Generic Name:  
Code Name: SNS01-T
Company: Senesco
FDA Clinical Phase: 1/2

Description:
SNS01-T is a small inhibitory RNA molecule that blocks the expression of Factor 5A mRNA. The Factor 5A gene has been shown to regulate the expression of …

Page 1 of 612345...Last »